Global Single-Domain Antibody Therapeutics Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Single-Domain Antibody Therapeutics market size was valued at US$ 517 million in 2025 and is forecast to a readjusted size of US$ 1132 million by 2032 with a CAGR of 11.6% during review period.
Single-domain antibody therapeutics are biologic treatments developed around a single antibody variable domain, including VHH, human VH, human VL, and VNAR domains. These domains can be linked, fused, conjugated, or assembled into monovalent, bivalent, multivalent, multispecific, Fc-fusion, and albumin-binding half-life-extended formats. Major therapeutic applications include hematological disorders, autoimmune and inflammatory diseases, oncology, respiratory diseases, and infectious diseases. Representative commercialized products include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab developed by Alphamab Oncology, while a growing number of multivalent, multispecific, and inhaled single-domain antibody candidates remain in clinical development. Key upstream inputs include antibody discovery and display libraries, engineered production cell lines, culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, linkers, sterile filling components, vials or prefilled syringes, and cold-chain packaging materials. Downstream users and treatment settings include pharmaceutical and biotechnology companies, hospitals, specialty treatment centers, and clinical departments specializing in hematology, rheumatology, oncology, and respiratory medicine. Based on commercial drug shipments at ex-factory prices, global nominal production capacity in 2025 is estimated at approximately 1.25 million units, with actual sales volume of around 728,000 units, an average ex-factory price of approximately USD 690 per unit, and an overall industry gross margin of about 70%?85%.
The single-domain antibody therapeutics market has progressed from early platform validation toward a stage where commercial products and clinical pipelines coexist. Approved therapies have established clinical use in hematological disorders, autoimmune diseases, and oncology, although the total number of marketed products remains considerably smaller than that of conventional full-length monoclonal antibodies. The competitive landscape consists of a limited number of mature platform owners and a broader group of clinical-stage biotechnology companies. Leading participants benefit from antibody discovery capabilities, molecular engineering expertise, clinical development experience, and global commercialization infrastructure. Companies in China, the United States, Europe, and Japan are also developing differentiated strategies in subcutaneous administration, inhaled delivery, multispecific formats, and local treatment. Future development is expected to move further toward multivalent, multispecific, half-life-extended, and tissue-targeted formats. The small size and relatively simple structure of single-domain antibodies make them suitable for linking multiple binding domains, albumin-binding modules, Fc regions, and functional effector units within one molecule. This enables developers to adjust potency, pharmacokinetics, tissue distribution, and dosing frequency. Advances in protein engineering may expand the modality from single-target blockade to dual-pathway inhibition, receptor agonism, immune-cell engagement, and targeted payload delivery. Inhaled, local, and mucosal administration may also become increasingly important, particularly in respiratory, ophthalmic, gastrointestinal, and localized inflammatory diseases. Market growth is being supported by unmet medical needs, the tissue penetration limitations of conventional antibodies, rising demand for multispecific biologics, and the development of more convenient administration routes. Single-domain antibodies can potentially access tissue compartments that are less accessible to full-length antibodies and may be produced through microbial or mammalian expression systems, providing flexibility for concentrated formulations, subcutaneous dosing, and local delivery. Acquisitions, licensing agreements, and co-development partnerships involving large pharmaceutical companies are also accelerating clinical development and global registration. As more candidates reach late-stage trials and demonstrate clear therapeutic differentiation, the modality may expand further across autoimmune disease, inflammation, oncology, respiratory disease, and rare disease treatment. The main barriers include short natural half-life, rapid renal clearance, potential immunogenicity associated with certain animal-derived sequences, and the increasing complexity of multidomain molecules. Developers often use albumin-binding domains, Fc fusion, or other half-life-extension technologies to improve systemic exposure, but these modifications may reduce some of the size and tissue penetration advantages of standalone domains. Multivalent and multispecific formats can also create challenges involving aggregation, stability, expression yield, analytical characterization, and batch consistency. From a commercial perspective, single-domain therapeutics compete with conventional monoclonal antibodies, biosimilars, small-molecule drugs, and alternative antibody formats. Broader adoption will therefore depend on demonstrating clear advantages in efficacy, safety, administration convenience, or treatment economics.
This report is a detailed and comprehensive analysis for global Single-Domain Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Single-Domain Antibody Therapeutics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single-Domain Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single-Domain Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single-Domain Antibody Therapeutics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Single-Domain Antibody Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Single-domain antibody therapeutics are biologic treatments developed around a single antibody variable domain, including VHH, human VH, human VL, and VNAR domains. These domains can be linked, fused, conjugated, or assembled into monovalent, bivalent, multivalent, multispecific, Fc-fusion, and albumin-binding half-life-extended formats. Major therapeutic applications include hematological disorders, autoimmune and inflammatory diseases, oncology, respiratory diseases, and infectious diseases. Representative commercialized products include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab developed by Alphamab Oncology, while a growing number of multivalent, multispecific, and inhaled single-domain antibody candidates remain in clinical development. Key upstream inputs include antibody discovery and display libraries, engineered production cell lines, culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, linkers, sterile filling components, vials or prefilled syringes, and cold-chain packaging materials. Downstream users and treatment settings include pharmaceutical and biotechnology companies, hospitals, specialty treatment centers, and clinical departments specializing in hematology, rheumatology, oncology, and respiratory medicine. Based on commercial drug shipments at ex-factory prices, global nominal production capacity in 2025 is estimated at approximately 1.25 million units, with actual sales volume of around 728,000 units, an average ex-factory price of approximately USD 690 per unit, and an overall industry gross margin of about 70%?85%.
The single-domain antibody therapeutics market has progressed from early platform validation toward a stage where commercial products and clinical pipelines coexist. Approved therapies have established clinical use in hematological disorders, autoimmune diseases, and oncology, although the total number of marketed products remains considerably smaller than that of conventional full-length monoclonal antibodies. The competitive landscape consists of a limited number of mature platform owners and a broader group of clinical-stage biotechnology companies. Leading participants benefit from antibody discovery capabilities, molecular engineering expertise, clinical development experience, and global commercialization infrastructure. Companies in China, the United States, Europe, and Japan are also developing differentiated strategies in subcutaneous administration, inhaled delivery, multispecific formats, and local treatment. Future development is expected to move further toward multivalent, multispecific, half-life-extended, and tissue-targeted formats. The small size and relatively simple structure of single-domain antibodies make them suitable for linking multiple binding domains, albumin-binding modules, Fc regions, and functional effector units within one molecule. This enables developers to adjust potency, pharmacokinetics, tissue distribution, and dosing frequency. Advances in protein engineering may expand the modality from single-target blockade to dual-pathway inhibition, receptor agonism, immune-cell engagement, and targeted payload delivery. Inhaled, local, and mucosal administration may also become increasingly important, particularly in respiratory, ophthalmic, gastrointestinal, and localized inflammatory diseases. Market growth is being supported by unmet medical needs, the tissue penetration limitations of conventional antibodies, rising demand for multispecific biologics, and the development of more convenient administration routes. Single-domain antibodies can potentially access tissue compartments that are less accessible to full-length antibodies and may be produced through microbial or mammalian expression systems, providing flexibility for concentrated formulations, subcutaneous dosing, and local delivery. Acquisitions, licensing agreements, and co-development partnerships involving large pharmaceutical companies are also accelerating clinical development and global registration. As more candidates reach late-stage trials and demonstrate clear therapeutic differentiation, the modality may expand further across autoimmune disease, inflammation, oncology, respiratory disease, and rare disease treatment. The main barriers include short natural half-life, rapid renal clearance, potential immunogenicity associated with certain animal-derived sequences, and the increasing complexity of multidomain molecules. Developers often use albumin-binding domains, Fc fusion, or other half-life-extension technologies to improve systemic exposure, but these modifications may reduce some of the size and tissue penetration advantages of standalone domains. Multivalent and multispecific formats can also create challenges involving aggregation, stability, expression yield, analytical characterization, and batch consistency. From a commercial perspective, single-domain therapeutics compete with conventional monoclonal antibodies, biosimilars, small-molecule drugs, and alternative antibody formats. Broader adoption will therefore depend on demonstrating clear advantages in efficacy, safety, administration convenience, or treatment economics.
This report is a detailed and comprehensive analysis for global Single-Domain Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Single-Domain Antibody Therapeutics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single-Domain Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single-Domain Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Single-Domain Antibody Therapeutics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Single-Domain Antibody Therapeutics
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Single-Domain Antibody Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Cablivi
- Nanozora
- Envafolimab
- Subcutaneous Injection
- Intravenous Injection
- Other
- Online Sales
- Offline Sales
- Hospital
- Clinic
- Others
- Sanofi
- Taisho Pharmaceutical
- Alphamab Oncology
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
- Chapter 1, to describe Single-Domain Antibody Therapeutics product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top manufacturers of Single-Domain Antibody Therapeutics, with price, sales quantity, revenue, and global market share of Single-Domain Antibody Therapeutics from 2021 to 2026.
- Chapter 3, the Single-Domain Antibody Therapeutics competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
- Chapter 4, the Single-Domain Antibody Therapeutics breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
- Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Single-Domain Antibody Therapeutics market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
- Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
- Chapter 13, the key raw materials and key suppliers, and industry chain of Single-Domain Antibody Therapeutics.
- Chapter 14 and 15, to describe Single-Domain Antibody Therapeutics sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Cablivi
1.3.3 Nanozora
1.3.4 Envafolimab
1.4 Market Analysis by Administration Route
1.4.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
1.4.2 Subcutaneous Injection
1.4.3 Intravenous Injection
1.4.4 Other
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Online Sales
1.5.3 Offline Sales
1.6 Market Analysis by Application
1.6.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Single-Domain Antibody Therapeutics Market Size & Forecast
1.7.1 Global Single-Domain Antibody Therapeutics Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Single-Domain Antibody Therapeutics Sales Quantity (2021-2032)
1.7.3 Global Single-Domain Antibody Therapeutics Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Single-Domain Antibody Therapeutics Product and Services
2.1.4 Sanofi Single-Domain Antibody Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Sanofi Recent Developments/Updates
2.2 Taisho Pharmaceutical
2.2.1 Taisho Pharmaceutical Details
2.2.2 Taisho Pharmaceutical Major Business
2.2.3 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
2.2.4 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Taisho Pharmaceutical Recent Developments/Updates
2.3 Alphamab Oncology
2.3.1 Alphamab Oncology Details
2.3.2 Alphamab Oncology Major Business
2.3.3 Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
2.3.4 Alphamab Oncology Single-Domain Antibody Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Alphamab Oncology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SINGLE-DOMAIN ANTIBODY THERAPEUTICS BY MANUFACTURER
3.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Manufacturer (2021-2026)
3.2 Global Single-Domain Antibody Therapeutics Revenue by Manufacturer (2021-2026)
3.3 Global Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Single-Domain Antibody Therapeutics by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Single-Domain Antibody Therapeutics Manufacturer Market Share in 2025
3.4.3 Top 6 Single-Domain Antibody Therapeutics Manufacturer Market Share in 2025
3.5 Single-Domain Antibody Therapeutics Market: Overall Company Footprint Analysis
3.5.1 Single-Domain Antibody Therapeutics Market: Region Footprint
3.5.2 Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
3.5.3 Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Single-Domain Antibody Therapeutics Market Size by Region
4.1.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2032)
4.1.2 Global Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2032)
4.1.3 Global Single-Domain Antibody Therapeutics Average Price by Region (2021-2032)
4.2 North America Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.3 Europe Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.4 Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.5 South America Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.6 Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
5.2 Global Single-Domain Antibody Therapeutics Consumption Value by Type (2021-2032)
5.3 Global Single-Domain Antibody Therapeutics Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
6.2 Global Single-Domain Antibody Therapeutics Consumption Value by Application (2021-2032)
6.3 Global Single-Domain Antibody Therapeutics Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
7.2 North America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
7.3 North America Single-Domain Antibody Therapeutics Market Size by Country
7.3.1 North America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
7.3.2 North America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
8.2 Europe Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
8.3 Europe Single-Domain Antibody Therapeutics Market Size by Country
8.3.1 Europe Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
8.3.2 Europe Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Single-Domain Antibody Therapeutics Market Size by Region
9.3.1 Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
10.2 South America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
10.3 South America Single-Domain Antibody Therapeutics Market Size by Country
10.3.1 South America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
10.3.2 South America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Single-Domain Antibody Therapeutics Market Size by Country
11.3.1 Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Single-Domain Antibody Therapeutics Market Drivers
12.2 Single-Domain Antibody Therapeutics Market Restraints
12.3 Single-Domain Antibody Therapeutics Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Single-Domain Antibody Therapeutics and Key Manufacturers
13.2 Manufacturing Costs Percentage of Single-Domain Antibody Therapeutics
13.3 Single-Domain Antibody Therapeutics Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Single-Domain Antibody Therapeutics Typical Distributors
14.3 Single-Domain Antibody Therapeutics Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Cablivi
1.3.3 Nanozora
1.3.4 Envafolimab
1.4 Market Analysis by Administration Route
1.4.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032
1.4.2 Subcutaneous Injection
1.4.3 Intravenous Injection
1.4.4 Other
1.5 Market Analysis by Sales Channels
1.5.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.5.2 Online Sales
1.5.3 Offline Sales
1.6 Market Analysis by Application
1.6.1 Overview: Global Single-Domain Antibody Therapeutics Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Single-Domain Antibody Therapeutics Market Size & Forecast
1.7.1 Global Single-Domain Antibody Therapeutics Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Single-Domain Antibody Therapeutics Sales Quantity (2021-2032)
1.7.3 Global Single-Domain Antibody Therapeutics Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Single-Domain Antibody Therapeutics Product and Services
2.1.4 Sanofi Single-Domain Antibody Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Sanofi Recent Developments/Updates
2.2 Taisho Pharmaceutical
2.2.1 Taisho Pharmaceutical Details
2.2.2 Taisho Pharmaceutical Major Business
2.2.3 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
2.2.4 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Taisho Pharmaceutical Recent Developments/Updates
2.3 Alphamab Oncology
2.3.1 Alphamab Oncology Details
2.3.2 Alphamab Oncology Major Business
2.3.3 Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
2.3.4 Alphamab Oncology Single-Domain Antibody Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Alphamab Oncology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: SINGLE-DOMAIN ANTIBODY THERAPEUTICS BY MANUFACTURER
3.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Manufacturer (2021-2026)
3.2 Global Single-Domain Antibody Therapeutics Revenue by Manufacturer (2021-2026)
3.3 Global Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Single-Domain Antibody Therapeutics by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Single-Domain Antibody Therapeutics Manufacturer Market Share in 2025
3.4.3 Top 6 Single-Domain Antibody Therapeutics Manufacturer Market Share in 2025
3.5 Single-Domain Antibody Therapeutics Market: Overall Company Footprint Analysis
3.5.1 Single-Domain Antibody Therapeutics Market: Region Footprint
3.5.2 Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
3.5.3 Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Single-Domain Antibody Therapeutics Market Size by Region
4.1.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2032)
4.1.2 Global Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2032)
4.1.3 Global Single-Domain Antibody Therapeutics Average Price by Region (2021-2032)
4.2 North America Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.3 Europe Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.4 Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.5 South America Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
4.6 Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
5.2 Global Single-Domain Antibody Therapeutics Consumption Value by Type (2021-2032)
5.3 Global Single-Domain Antibody Therapeutics Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
6.2 Global Single-Domain Antibody Therapeutics Consumption Value by Application (2021-2032)
6.3 Global Single-Domain Antibody Therapeutics Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
7.2 North America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
7.3 North America Single-Domain Antibody Therapeutics Market Size by Country
7.3.1 North America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
7.3.2 North America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
8.2 Europe Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
8.3 Europe Single-Domain Antibody Therapeutics Market Size by Country
8.3.1 Europe Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
8.3.2 Europe Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Single-Domain Antibody Therapeutics Market Size by Region
9.3.1 Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
10.2 South America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
10.3 South America Single-Domain Antibody Therapeutics Market Size by Country
10.3.1 South America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
10.3.2 South America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Single-Domain Antibody Therapeutics Market Size by Country
11.3.1 Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Single-Domain Antibody Therapeutics Market Drivers
12.2 Single-Domain Antibody Therapeutics Market Restraints
12.3 Single-Domain Antibody Therapeutics Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Single-Domain Antibody Therapeutics and Key Manufacturers
13.2 Manufacturing Costs Percentage of Single-Domain Antibody Therapeutics
13.3 Single-Domain Antibody Therapeutics Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Single-Domain Antibody Therapeutics Typical Distributors
14.3 Single-Domain Antibody Therapeutics Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Single-Domain Antibody Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Single-Domain Antibody Therapeutics Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 3. Global Single-Domain Antibody Therapeutics Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Single-Domain Antibody Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Sanofi Basic Information, Manufacturing Base and Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Single-Domain Antibody Therapeutics Product and Services
Table 8. Sanofi Single-Domain Antibody Therapeutics Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Sanofi Recent Developments/Updates
Table 10. Taisho Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 11. Taisho Pharmaceutical Major Business
Table 12. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
Table 13. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Taisho Pharmaceutical Recent Developments/Updates
Table 15. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 16. Alphamab Oncology Major Business
Table 17. Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
Table 18. Alphamab Oncology Single-Domain Antibody Therapeutics Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Alphamab Oncology Recent Developments/Updates
Table 20. Global Single-Domain Antibody Therapeutics Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 21. Global Single-Domain Antibody Therapeutics Revenue by Manufacturer (2021-2026) & (USD Million)
Table 22. Global Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 23. Market Position of Manufacturers in Single-Domain Antibody Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 24. Head Office and Single-Domain Antibody Therapeutics Production Site of Key Manufacturer
Table 25. Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
Table 26. Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
Table 27. Single-Domain Antibody Therapeutics New Market Entrants and Barriers to Market Entry
Table 28. Single-Domain Antibody Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 29. Global Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 30. Global Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2026) & (K Units)
Table 31. Global Single-Domain Antibody Therapeutics Sales Quantity by Region (2027-2032) & (K Units)
Table 32. Global Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 33. Global Single-Domain Antibody Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 34. Global Single-Domain Antibody Therapeutics Average Price by Region (2021-2026) & (US$/Unit)
Table 35. Global Single-Domain Antibody Therapeutics Average Price by Region (2027-2032) & (US$/Unit)
Table 36. Global Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 37. Global Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 38. Global Single-Domain Antibody Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 39. Global Single-Domain Antibody Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 40. Global Single-Domain Antibody Therapeutics Average Price by Type (2021-2026) & (US$/Unit)
Table 41. Global Single-Domain Antibody Therapeutics Average Price by Type (2027-2032) & (US$/Unit)
Table 42. Global Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 43. Global Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 44. Global Single-Domain Antibody Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 45. Global Single-Domain Antibody Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 46. Global Single-Domain Antibody Therapeutics Average Price by Application (2021-2026) & (US$/Unit)
Table 47. Global Single-Domain Antibody Therapeutics Average Price by Application (2027-2032) & (US$/Unit)
Table 48. North America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 49. North America Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 50. North America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 51. North America Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 52. North America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 53. North America Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 54. North America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 55. North America Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 56. Europe Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 57. Europe Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 58. Europe Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 59. Europe Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 60. Europe Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 61. Europe Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 62. Europe Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 63. Europe Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 64. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 65. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 66. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 67. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 68. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2026) & (K Units)
Table 69. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Region (2027-2032) & (K Units)
Table 70. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 71. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 72. South America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 73. South America Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 74. South America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 75. South America Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 76. South America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 77. South America Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 78. South America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 79. South America Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 80. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 81. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 82. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 83. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 84. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 85. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 86. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 87. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 88. Single-Domain Antibody Therapeutics Raw Material
Table 89. Key Manufacturers of Single-Domain Antibody Therapeutics Raw Materials
Table 90. Single-Domain Antibody Therapeutics Typical Distributors
Table 91. Single-Domain Antibody Therapeutics Typical Customers
Table 1. Global Single-Domain Antibody Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Single-Domain Antibody Therapeutics Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 3. Global Single-Domain Antibody Therapeutics Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 4. Global Single-Domain Antibody Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Sanofi Basic Information, Manufacturing Base and Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Single-Domain Antibody Therapeutics Product and Services
Table 8. Sanofi Single-Domain Antibody Therapeutics Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Sanofi Recent Developments/Updates
Table 10. Taisho Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 11. Taisho Pharmaceutical Major Business
Table 12. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
Table 13. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Taisho Pharmaceutical Recent Developments/Updates
Table 15. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 16. Alphamab Oncology Major Business
Table 17. Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
Table 18. Alphamab Oncology Single-Domain Antibody Therapeutics Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Alphamab Oncology Recent Developments/Updates
Table 20. Global Single-Domain Antibody Therapeutics Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 21. Global Single-Domain Antibody Therapeutics Revenue by Manufacturer (2021-2026) & (USD Million)
Table 22. Global Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 23. Market Position of Manufacturers in Single-Domain Antibody Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 24. Head Office and Single-Domain Antibody Therapeutics Production Site of Key Manufacturer
Table 25. Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
Table 26. Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
Table 27. Single-Domain Antibody Therapeutics New Market Entrants and Barriers to Market Entry
Table 28. Single-Domain Antibody Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 29. Global Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 30. Global Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2026) & (K Units)
Table 31. Global Single-Domain Antibody Therapeutics Sales Quantity by Region (2027-2032) & (K Units)
Table 32. Global Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 33. Global Single-Domain Antibody Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 34. Global Single-Domain Antibody Therapeutics Average Price by Region (2021-2026) & (US$/Unit)
Table 35. Global Single-Domain Antibody Therapeutics Average Price by Region (2027-2032) & (US$/Unit)
Table 36. Global Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 37. Global Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 38. Global Single-Domain Antibody Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 39. Global Single-Domain Antibody Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 40. Global Single-Domain Antibody Therapeutics Average Price by Type (2021-2026) & (US$/Unit)
Table 41. Global Single-Domain Antibody Therapeutics Average Price by Type (2027-2032) & (US$/Unit)
Table 42. Global Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 43. Global Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 44. Global Single-Domain Antibody Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 45. Global Single-Domain Antibody Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 46. Global Single-Domain Antibody Therapeutics Average Price by Application (2021-2026) & (US$/Unit)
Table 47. Global Single-Domain Antibody Therapeutics Average Price by Application (2027-2032) & (US$/Unit)
Table 48. North America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 49. North America Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 50. North America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 51. North America Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 52. North America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 53. North America Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 54. North America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 55. North America Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 56. Europe Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 57. Europe Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 58. Europe Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 59. Europe Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 60. Europe Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 61. Europe Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 62. Europe Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 63. Europe Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 64. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 65. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 66. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 67. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 68. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Region (2021-2026) & (K Units)
Table 69. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity by Region (2027-2032) & (K Units)
Table 70. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 71. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 72. South America Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 73. South America Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 74. South America Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 75. South America Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 76. South America Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 77. South America Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 78. South America Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 79. South America Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 80. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Type (2021-2026) & (K Units)
Table 81. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Type (2027-2032) & (K Units)
Table 82. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Application (2021-2026) & (K Units)
Table 83. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Application (2027-2032) & (K Units)
Table 84. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Country (2021-2026) & (K Units)
Table 85. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity by Country (2027-2032) & (K Units)
Table 86. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 87. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 88. Single-Domain Antibody Therapeutics Raw Material
Table 89. Key Manufacturers of Single-Domain Antibody Therapeutics Raw Materials
Table 90. Single-Domain Antibody Therapeutics Typical Distributors
Table 91. Single-Domain Antibody Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. Single-Domain Antibody Therapeutics Picture
Figure 2. Global Single-Domain Antibody Therapeutics Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Single-Domain Antibody Therapeutics Revenue Market Share by Type in 2025
Figure 4. Cablivi Examples
Figure 5. Nanozora Examples
Figure 6. Envafolimab Examples
Figure 7. Global Single-Domain Antibody Therapeutics Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Single-Domain Antibody Therapeutics Revenue Market Share by Administration Route in 2025
Figure 9. Subcutaneous Injection Examples
Figure 10. Intravenous Injection Examples
Figure 11. Other Examples
Figure 12. Global Single-Domain Antibody Therapeutics Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Single-Domain Antibody Therapeutics Revenue Market Share by Sales Channels in 2025
Figure 14. Online Sales Examples
Figure 15. Offline Sales Examples
Figure 16. Global Single-Domain Antibody Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 17. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application in 2025
Figure 18. Hospital Examples
Figure 19. Clinic Examples
Figure 20. Others Examples
Figure 21. Global Single-Domain Antibody Therapeutics Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Single-Domain Antibody Therapeutics Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Single-Domain Antibody Therapeutics Sales Quantity (2021-2032) & (K Units)
Figure 24. Global Single-Domain Antibody Therapeutics Price (2021-2032) & (US$/Unit)
Figure 25. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Manufacturer in 2025
Figure 26. Global Single-Domain Antibody Therapeutics Revenue Market Share by Manufacturer in 2025
Figure 27. Producer Shipments of Single-Domain Antibody Therapeutics by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 28. Top 3 Single-Domain Antibody Therapeutics Manufacturer (Revenue) Market Share in 2025
Figure 29. Top 6 Single-Domain Antibody Therapeutics Manufacturer (Revenue) Market Share in 2025
Figure 30. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Region (2021-2032)
Figure 31. Global Single-Domain Antibody Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 32. North America Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 33. Europe Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 34. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 35. South America Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 36. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 37. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 38. Global Single-Domain Antibody Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 39. Global Single-Domain Antibody Therapeutics Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 41. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application (2021-2032)
Figure 42. Global Single-Domain Antibody Therapeutics Average Price by Application (2021-2032) & (US$/Unit)
Figure 43. North America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 44. North America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 45. North America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 46. North America Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 47. United States Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 48. Canada Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 49. Mexico Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 50. Europe Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 51. Europe Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 52. Europe Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 53. Europe Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 55. France Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity Market Share by Region (2021-2032)
Figure 62. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 63. China Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 64. Japan Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 65. South Korea Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 66. India Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 67. Southeast Asia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 68. Australia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 69. South America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 70. South America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 71. South America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 72. South America Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 73. Brazil Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 74. Argentina Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 75. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 76. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 77. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 78. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 79. Turkey Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 80. Egypt Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 81. Saudi Arabia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 82. South Africa Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 83. Single-Domain Antibody Therapeutics Market Drivers
Figure 84. Single-Domain Antibody Therapeutics Market Restraints
Figure 85. Single-Domain Antibody Therapeutics Market Trends
Figure 86. Porters Five Forces Analysis
Figure 87. Manufacturing Cost Structure Analysis of Single-Domain Antibody Therapeutics in 2025
Figure 88. Manufacturing Process Analysis of Single-Domain Antibody Therapeutics
Figure 89. Single-Domain Antibody Therapeutics Industrial Chain
Figure 90. Sales Channel: Direct to End-User vs Distributors
Figure 91. Direct Channel Pros & Cons
Figure 92. Indirect Channel Pros & Cons
Figure 93. Methodology
Figure 94. Research Process and Data Source
Figure 1. Single-Domain Antibody Therapeutics Picture
Figure 2. Global Single-Domain Antibody Therapeutics Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Single-Domain Antibody Therapeutics Revenue Market Share by Type in 2025
Figure 4. Cablivi Examples
Figure 5. Nanozora Examples
Figure 6. Envafolimab Examples
Figure 7. Global Single-Domain Antibody Therapeutics Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Single-Domain Antibody Therapeutics Revenue Market Share by Administration Route in 2025
Figure 9. Subcutaneous Injection Examples
Figure 10. Intravenous Injection Examples
Figure 11. Other Examples
Figure 12. Global Single-Domain Antibody Therapeutics Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Single-Domain Antibody Therapeutics Revenue Market Share by Sales Channels in 2025
Figure 14. Online Sales Examples
Figure 15. Offline Sales Examples
Figure 16. Global Single-Domain Antibody Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 17. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application in 2025
Figure 18. Hospital Examples
Figure 19. Clinic Examples
Figure 20. Others Examples
Figure 21. Global Single-Domain Antibody Therapeutics Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Single-Domain Antibody Therapeutics Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Single-Domain Antibody Therapeutics Sales Quantity (2021-2032) & (K Units)
Figure 24. Global Single-Domain Antibody Therapeutics Price (2021-2032) & (US$/Unit)
Figure 25. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Manufacturer in 2025
Figure 26. Global Single-Domain Antibody Therapeutics Revenue Market Share by Manufacturer in 2025
Figure 27. Producer Shipments of Single-Domain Antibody Therapeutics by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 28. Top 3 Single-Domain Antibody Therapeutics Manufacturer (Revenue) Market Share in 2025
Figure 29. Top 6 Single-Domain Antibody Therapeutics Manufacturer (Revenue) Market Share in 2025
Figure 30. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Region (2021-2032)
Figure 31. Global Single-Domain Antibody Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 32. North America Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 33. Europe Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 34. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 35. South America Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 36. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 37. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 38. Global Single-Domain Antibody Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 39. Global Single-Domain Antibody Therapeutics Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. Global Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 41. Global Single-Domain Antibody Therapeutics Revenue Market Share by Application (2021-2032)
Figure 42. Global Single-Domain Antibody Therapeutics Average Price by Application (2021-2032) & (US$/Unit)
Figure 43. North America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 44. North America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 45. North America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 46. North America Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 47. United States Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 48. Canada Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 49. Mexico Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 50. Europe Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 51. Europe Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 52. Europe Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 53. Europe Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 55. France Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Single-Domain Antibody Therapeutics Sales Quantity Market Share by Region (2021-2032)
Figure 62. Asia-Pacific Single-Domain Antibody Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 63. China Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 64. Japan Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 65. South Korea Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 66. India Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 67. Southeast Asia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 68. Australia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 69. South America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 70. South America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 71. South America Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 72. South America Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 73. Brazil Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 74. Argentina Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 75. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity Market Share by Type (2021-2032)
Figure 76. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity Market Share by Application (2021-2032)
Figure 77. Middle East & Africa Single-Domain Antibody Therapeutics Sales Quantity Market Share by Country (2021-2032)
Figure 78. Middle East & Africa Single-Domain Antibody Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 79. Turkey Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 80. Egypt Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 81. Saudi Arabia Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 82. South Africa Single-Domain Antibody Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 83. Single-Domain Antibody Therapeutics Market Drivers
Figure 84. Single-Domain Antibody Therapeutics Market Restraints
Figure 85. Single-Domain Antibody Therapeutics Market Trends
Figure 86. Porters Five Forces Analysis
Figure 87. Manufacturing Cost Structure Analysis of Single-Domain Antibody Therapeutics in 2025
Figure 88. Manufacturing Process Analysis of Single-Domain Antibody Therapeutics
Figure 89. Single-Domain Antibody Therapeutics Industrial Chain
Figure 90. Sales Channel: Direct to End-User vs Distributors
Figure 91. Direct Channel Pros & Cons
Figure 92. Indirect Channel Pros & Cons
Figure 93. Methodology
Figure 94. Research Process and Data Source
